Agreement brings Access to US Haematology Therapy

Global pharmaceutical company and service partner Inceptua (Luxembourg) has signed a distribution partnership with Portola, a US developer and manufacturer of therapeutic agents focusing on thrombosis and other haematological conditions.

The agreement covers the distribution of Portola’s Ondexxya® therapeutic that has been approved by the US FDA and also by the EMA (26th April 2019). This recombinant modified human factor Xa (FXa) protein is intended for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

Through this agreement Inceptua becomes the exclusive distributor of Ondexxya® (andexanet alfa) in; Belgium, France, Ireland, Luxembourg, Norway, Portugal and Spain. Inceptua Medicines Access will be providing access to the product in these countries until the point at which Ondexxya® becomes commercially-available in each country.

For more information on the pre-approval access program visit www.inceptua.com